Furiex Pharmaceuticals, Inc. FURX today confirmed Takeda
Pharmaceutical Company Limited (Takeda)'s announcement that the European
Commission has granted Marketing Authorization (MA) for VIPIDIA™
(alogliptin) for the treatment of Type 2 diabetes patients who are
uncontrolled on existing therapies and for the fixed-dose combinations
VIPDOMET™ (alogliptin and metformin) and INCRESYNC™ (alogliptin and
pioglitazone). The Committee for Medicinal Products for Human Use
(CHMP), of the European Medicines Agency (EMA), issued a positive
opinion for these products on July 26, 2013.
Under its agreement with Takeda, the MA triggers a $10 million milestone
payment to Furiex. Furiex is also eligible to receive tiered royalties
on product sales in the EU and potential sales-based milestones.
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in